please help improve this article by adding citations to reliable sources . unsourced material may be challenged and removed . april 2013 learn how and when to remove this template message curevac gmbh . type private industry biotechnology headquarters t bingen germany website curevac.com curevac is a biopharmaceutical company headquartered in t bingen germany that develops therapies based on messenger rna mrna . 1 the main research primarily focuses on cancer immunotherapies and prophylactic vaccines against infectious diseases . 2 founded in 2000 curevac currently has about 240 employees . 3 since inception curevac had received approximately 330 million 300 million in equity investments . 4 curevac has entered into various collaborations with multinational corporations and organizations including agreements with boehringer ingelheim sanofi pasteur johnson & johnson the bill & melinda gates foundation and the international aids vaccine initiative . 5 contents 1 technology 2 research 3 history 4 references technology edit curevac s technology platform was developed in the late 1990s from the research conducted by ingmar hoerr and colleagues in the laboratories of professor hans georg rammensee and professor g nther jung at university of t bingen in germany . 6 curevac s technology platform utilizes natural chemically unmodified mrna which studies have shown elicits great therapeutic responses . 7 the basic principle of the company s proprietary technology is the use of mrna as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases . 8 since 2008 curevac has applied its mrna technology in more than 350 humans in seven clinical trials in eleven countries including an ongoing phase iib trial in prostate cancer . 9 curevac s mrna programs include novel mrna based cancer immunotherapies and prophylactic vaccines against infectious diseases rnactive molecular therapies designed to trigger the body s own production of therapeutic proteins rnart and rna encoded antibodies rnantibody . 10 curevac s development pipeline also includes clinical programs in non small cell lung cancer partnered with boehringer ingelheim and rabies as well as numerous development programs including hiv rotavirus rsv tuberculosis and further indications that are mostly part of strategic partnerships with pharma companies and ngos . 11 in 2006 curevac successfully established the first gmp facility worldwide for the manufacturing of mrna for medical purposes . 12 in 2016 curevac will start the construction of an industrial scale production facility with a capacity of 30 million doses per year . 13 research edit researchers from curevac published data in nature biotechnology in 2012 which highlighted an experimental rna vaccine approach for longer protection from flu . 14 in june 2015 curevac announced that a study of its rnart technology platform was published in the peer reviewed journal molecular therapy demonstrating for the first time ever that sequence optimized chemically unmodified mrnas raised relevant protein levels in non human primates without stimulating unwanted immune reaction indicating that mrna achieves meaningful biological effects in large animals with body weight close to humans . 15 the study also suggested that sequence optimized unmodified mrnas offer advantages when compared to chemically modified mrnas including more efficacious protein translation . 16 in july 2015 curevac announced a publication in the peer reviewed journal for immunotherapy of cancer highlighting a phase i iia study of the company s mrna cancer immunotherapy cv9103 in advanced castration resistant prostate cancer . the data showed the first phase iia clinical study in which an mrna therapy has demonstrated antigen specific immune responses in the majority of patients . 17 history edit in october 2013 curevac launched a collaboration with janssen pharmaceuticals inc. a johnson & johnson company for the development of novel flu vaccines . 18 in november 2013 curevac announced the fourth in a series of partnerships with the cancer research institute and ludwig cancer research to enable clinical testing of novel cancer immunotherapy treatment options . 19 on march 10 2014 curevac won a 2 million prize awarded by the european commission to stimulate new vaccine technologies that might help the developing world because the company s research could lead to a new generation of vaccines that don t need refrigeration . 20 in july 2014 curevac signed an exclusive license agreement with sanofi pasteur to develop and commercialize an mrna based prophylactic vaccine . 21 in september 2014 the company licensed the global rights for its phase i candidate cv9202 to boehringer ingelheim . boehringer plans to conduct trials using the mrna vaccine in combination with afatinib in advanced and or metastatic epidermal growth factor receptor egfr mutated non small cell lung cancer nsclc as well as inoperable stage iii nsclc . this could culminate in netting the company approximately 600 million . 22 in march 2015 curevac s investor the bill & melinda gates foundation agreed to provide separate funding for several projects to develop prophylactic vaccines based on curevac s proprietary mrna platform . 23 in august 2015 curevac announced the initiation of its third target product development program in collaboration with the bill & melinda gates foundation . the program will leverage curevac s rnactive technology platform in the development of a prophylactic vaccine to protect against respiratory syncytial virus rsv adding to the development programs previously initiated by curevac and the gates foundation targeting mrna vaccines for hiv and rotavirus . 24 in september 2015 curevac entered into a collaboration with the international aids vaccine initiative iavi to accelerate the development of aids vaccines utilizing immunogens developed by iavi and partners delivered via curevac s mrna technology . 25 in november 2015 curevac raised about 110 million 100 million in a private placement to enable expansion of its mrna development platform and clinical stage pipeline . curevac also announced the change of its corporate legal form to a joint stock company aktiengesellschaft ag . this new financing round was led by baillie gifford adding to the approximately 220 million curevac has raised since its founding in 2000 . the new investors baillie gifford chartwave limited coppel family northview and sigma group join existing investors dievini hopp biotech holding gmbh & co. kg of dietmar hopp and the bill & melinda gates foundation . 26 references edit feature in fierce biotech sp2 inter active . september october 2012 . gates hopp back 110m megaround for curevac s mrna work . gates hopp back 110m megaround for curevac s mrna work . curevac opens up an mrna hub in moderna s cambridge backyard . in vivo application of rna leads to induction of specific cytotoxic t lymphocytes and antibodies . eur j immunol . 30 1 1 7 . jan 2000 . doi 10.1002 1521 4141 200001 30 11 aid immu13 .0 . co ; 2 . pmid 10602021 . sequence engineered mrna without chemical nucleoside modifications enables an effective protein therapy in large animals . mol ther . 23 9 1456 1464 . sep 2015 . doi 10.1038 mt. 2015.103 . conversation on curevac s rna based therapeutics with ceo ingmar hoerr . vantage point the messenger comes calling . conversation on curevac s rna based therapeutics with ceo ingmar hoerr . gates hopp back 110m megaround for curevac s mrna work . german rna vaccines company bags 2 million e.u. vaccine prize . vantage point the messenger comes calling . protective efficacy of in vitro synthesized specific mrna vaccines against influenza a virus infection . nat biotechnol . 30 12 1210 1216 . dec 2012 . doi 10.1038 nbt .2436 . sequence engineered mrna without chemical nucleoside modifications enables an effective protein therapy in large animals . mol ther . 23 9 1456 1464 . sep 2015 . doi 10.1038 mt. 2015.103 . sequence engineered mrna without chemical nucleoside modifications enables an effective protein therapy in large animals . mol ther . 23 9 1456 1464 . sep 2015 . doi 10.1038 mt. 2015.103 . self adjuvanted mrna vaccination in advanced prostate cancer patients a first in man phase i iia study . jitc . 3 26 . june 2015 . j & j s janssen companies launch a trio of collaborations . cri ludwig to test cancer immunotherapy combinations with curevac . german rna vaccines company bags 2 million e.u. vaccine prize . curevac sanofi paster in 150m euro plus vaccines deal . boehringer pairs its lung cancer drug with a vaccine in 600m tie up with curevac . bill and melinda gates foundation makes its largest ever equity investment in a biotech company . bill & melinda gates faith in curevac is leading to a new program . iavi and curevac partner to further aids vaccine candidates . gates hopp back 110m megaround for curevac s mrna work . retrieved from https en.wikipedia.org w index.php title curevac & oldid 732876195 categories biopharmaceutical companiescancer organizationshealth care companies of germanyhidden categories articles needing additional references from april 2013all articles needing additional references navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page print export create a bookdownload as pdfprintable version languages deutsch edit links this page was last modified on 3 august 2016 at 20 37 . text is available under the creative commons attribution sharealike license ; additional terms may apply . by using this site you agree to the terms of use and privacy policy . wikipedia is a registered trademark of the wikimedia foundation inc. a non profit organization . privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view